Paul B. Manning is the founder, president, and chief executive officer of PBM Products, LLC, the first company to launch (private-label) store-brand infant formulas in the United States. He is also the founder, president, and chief executive officer of Beta-Pro LLC, a cellular therapy company for diabetes that supplies clinical-grade human islet cells to research organizations.

Before forming PBM in 1997, Mr. Manning held key sales and marketing positions with leading pharmaceutical companies and founded several companies, including Able Laboratories and Manfam, Inc., two companies that developed and distributed prescription and over-the-counter products to major chains in the United States.

Aside from his entrepreneurial work, Mr. Manning created the Islet Replacement Research Foundation, a voluntary nonprofit grant maker and supporter of diabetes research. The goal of the foundation is to bring together dedicated scientists who support ambitious research projects to find a cure for diabetes and eradicate insulin dependence.

To date PBM has donated several million dollars to diabetes research with the aim of giving everyone with diabetes the opportunity to live a life free from the constraints of insulin management. Mr. Manning has changed the name of his nonprofit organization to reflect his personal and corporate mission: Focus to Cure Diabetes Foundation.

Mr. Manning is a director of the National Neurovision Research Institute (NNRI), the clinical trial support organization of the Foundation Fighting Blindness (FFB). He is also an active member of the University of Virginia (U.Va.) Health Foundation Board of Trustees; these leaders from the private and public sectors work closely with the U.Va. Health System and the university’s leadership to foster philanthropy for the $500 million Campaign for Health.

In 2002, Mr. Manning was named Virginia Entrepreneur of the Year by Ernst & Young. He is a graduate of the University of Massachusetts, where he earned a BS in microbiology.